Mum1 mum1p

Paraffin-embedded sections of each sample were immunostained. The antibodies (clones) used for IHC were as follows: anti-CD10 (56C6; Leica Microsystems, Wetzler, Germany), anti-CD20 (L-26; Dakocytomation, Glostrup, Denmark), anti-BCL2 (124; Dakocytomation), anti-BCL6 (P1F6; Leica Microsystems), and MUM1 (MUM1p; Dakocytomation). Each case was considered positive if more than ∼30% of the neoplastic cells were positive.21 (link)

All immunohistochemical analyses of FFPET were carried out using an automated immunostainer (Bond‐max; Leica Microsystems, Wetzlar, Germany). The following primary antibodies and dilutions were used: CD20 (L26, 1:200), CD3 (PS‐1, 1:50), CD10 (56C6, 1:50), CD5 (4C7, 1:100), Ki‐67 (MIB‐1, 1:5000), LMP1 (1:10) (all Leica Microsystems); multiple myeloma oncogene 1 (MUM1) (MUM1p, 1:50), NFκB p65 (1:1000) (both from Dako, Glostrup, Denmark); BCL‐6 (D‐8, 1:100) (Santa Cruz Biotechnology, Santa Cruz, CA, USA); germinal center B‐cell expressed transcript 1 (GCET1) (RAM341, 1:100), NFκB p105/p50 (E381, 1:250) (Abcam, Cambridge, UK); NFκB2 p100/p52 (18D10, 1:100) (Cell Signaling Technology, Danvers, MA, USA); forkhead box protein P1 (FOXP1) (JC12, 1:500), and BACH2 (1:400) (both from Life Span Biosciences, Seattle, WA, USA). In situ hybridization with EBV‐encoded small RNA probes (Leica Microsystems) was used to detect EBV. A sample was scored as positive if >30% of the lymphoma cells were positively stained.